Filing Details
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
8k filedNASDAQ:AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Material Event to SEC
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
At publication ·
What changed
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Amylyx Pharmaceuticals filed a Form 8-K with the SEC on August 20, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock trades at $39.66 with a market capitalization of $1.3 billion as of the filing date.
- Form 8-K filings report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
Amylyx Pharmaceuticals, Inc.'s stock currently trades at $39.66 with a market capitalization of $1.3B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Amylyx Pharmaceuticals, Inc.'s stock.
All SEC filings for Amylyx Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AMLX Stock Page
Frequently Asked Questions
Where can I read AMLX's SEC filings?
Browse all filings on our AMLX SEC filings page.
What types of SEC filings does Amylyx Pharmaceuticals, Inc. file?
Public companies like Amylyx Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.